

10676089

=> d his

(FILE 'HOME' ENTERED AT 15:54:49 ON 02 APR 2004)

FILE 'REGISTRY' ENTERED AT 15:55:04 ON 02 APR 2004

L1 STRUCTURE UPLOADED  
L2 14 S L1  
L3 280 S L1 SSS FULL


FILE 'CAPLUS' ENTERED AT 15:56:01 ON 02 APR 2004

L4 21 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d 1-3 bib abs hitstr

L4 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:737516 CAPLUS  
DN 139:257284  
TI Cathepsin cysteine protease inhibitors and their therapeutic use  
IN Bayly, Christopher I.; Black, Cameron; Leger, Serge; Li, Chun Sing; McKay, Dan; Mellon, Christophe; Gauthier, Jacques Yves; Lau, Cheuk; Therien, Michel; Truong, Vouy-Linh; Green, Michael J.; Hirschbein, Bernard L.; Janc, James W.; Palmer, James T.; Baskaran, Chitra  
PA Merck Frosst Canada & Co., Can.; Axys Pharmaceuticals, Inc.  
SO PCT Int. Appl., 282 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003075836	A2	20030918	WO 2003-US6147	20030228
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,			

10676089

NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG

US 2003232863 A1 20031218 US 2003-377377 20030228  
PRAI US 2002-361818P P 20020305  
US 2002-408704P P 20020906

OS MARPAT 139:257284


AB This invention relates to cysteine protease inhibitors  
R7(D)nCR6R7NR8CR3R4C(:O)NHCR1R2CN (R1-4 = H, (substituted)C1-6-alkyl or  
C2-6-alkenyl; R1 and R2 or R3 and R4 may be taken together with the C atom  
to which they are attached to form a (substituted)C3-8-cycloalkyl or  
heterocyclic ring; R5 = H, (substituted)C1-6-alkyl; R6 =  
(substituted)aryl, heteroaryl, C1-6-haloalkyl, arylalkyl, heteroarylalkyl;  
D = (substituted)C1-3-alkyl, C2-3-alkenyl, C2-3-alkynyl, aryl, heteroaryl,  
C3-8-cycloalkyl, heterocyclyl; R7 = H, (substituted)C1-6-alkyl,  
C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, etc.; R8 = H, C2-6-alkyl)  
including but not limited to, inhibitors of cathepsins K, L, S and B.  
These compounds are useful for treating diseases in which inhibition of bone  
resorption is indicated, such as osteoporosis.

IT 603141-04-4P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(cathepsin cysteine protease inhibitors and their therapeutic use)

RN 603141-04-4 CAPLUS

CN Pentanamide, 2-[[[(1S)-1-[4-[(9-chloro-3-methyl-4-oxoisoxazolo[4,3-  
c]quinolin-5(4H)-yl)methyl]phenyl]-2,2,2-trifluoroethyl]amino]-N-  
(cyanomethyl)-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:496596 CAPLUS

DN 139:261215

TI Reaction of 1-alkyl/aryl-3-amino-1H,3H-quinoline-2,4-diones with urea.  
Synthetic route to novel 3-(3-acylureido)-2,3-dihydro-1H-indol-2-ones,  
4-alkylidene-1'H-spiro[imidazolidine-5,3'-indole]-2,2'-diones, and  
3,3a-dihydro-5H-imidazo[4,5-c]quinoline-2,4-diones

AU Klasek, Antonin; Koristek, Kamil; Lycka, Antonin; Holcapek, Michal

CS Faculty of Technology, Department of Chemistry and Environmental  
Technology, Tomas Bata University, Zlin, 762 72, Czech Rep.

SO Tetrahedron (2003), 59(28), 5279-5288  
CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier Science B.V.

DT Journal

LA English


OS CASREACT 139:261215

AB 1-Substituted 3-alkyl/aryl-3-amino-1H,3H-quinoline-2,4-diones react with  
urea in boiling acetic acid to give products which depend on the type of  
substitution in position 3 and at the nitrogen atom of the 3-amino group.  
Starting compounds bearing a primary amino group in position 3 give  
3-(3-acylureido)-2,3-dihydro-1H-indol-2-ones. Starting compounds bearing a  
secondary amino group in position 3 react according to the character of  
the other substituent in position 3. If there is a hydrogen atom  $\alpha$   
to the carbon atom C(3), 4-alkylidene-1'H-spiro[imidazolidine-5,3'-indole]-  
2,2'-diones arise. If a hydrogen atom is not present in this position,  
the reaction leads to 3,3a-dihydro-5H-imidazo[4,5-c]quinoline-2,4-diones.  
Reaction mechanisms for these transformations are proposed. All compounds  
were characterized by their <sup>1</sup>H, <sup>13</sup>C, IR and atmospheric pressure chemical ionization  
mass spectra and some of them also by <sup>15</sup>N NMR data.

IT 601520-25-6P  
RL: SPN (Synthetic preparation); PREP (Preparation)

10676089


(synthesis of indolones, spiro[imidazolidineindole]diones, and imidazoquinolinediones by reaction of aminoquinolinediones with urea)  
 RN 601520-25-6 CAPLUS  
 CN 2H-Imidazo[4,5-c]quinoline-2,4(5H)-dione, 3-butyl-3,3a-dihydro-3a,5-diphenyl- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:242160 CAPLUS  
 DN 138:271705  
 TI Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase  
 IN Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradel, Oscar; Leit, Silvana; Raepfel, Stephane; Frechette, Sylvie; Bouchain, Giliane  
 PA Methylgene, Inc., Can.  
 SO PCT Int. Appl., 347 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024448	A2	20030327	WO 2002-US29017	20020912
WO 2003024448	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2001-322402P	P	20010914		
US 2002-391728P	P	20020626		
OS MARPAT 138:271705				
GI				




AB The invention relates to triazines (shown as I; variables defined below; e.g. 4-[[4-amino-6-(2-indanylamino)-[1,3,5]triazin-2-ylamino]methyl]-N-(2-aminophenyl)benzamide) and Cy3-X1-Ar2-(C(R5):C(R6))qC(O)NH-Ay2 (II; variables defined below; e.g. ), many of which are N-(o-aminophenyl)carboxamides, as inhibitors of histone deacetylase (data included for many I and II). The invention provides compds. and methods for inhibiting histone deacetylase enzymic activity. The invention also provides compns. and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I and II are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. For I: R3 and R4 = H, L1, Cy1 and -L1-Cy1 (L1 = C1-C6

alkyl, C2-C6 heteroalkyl, or C3-C6 alkenyl; Cy1 = cycloalkyl, aryl, heteroaryl, or heterocyclyl) or R3 and R4 are taken together with the adjacent N atom to form a 5-, 6-, or 7-membered ring, wherein the ring atoms = C, O, S, and N, and wherein the ring is optionally substituted, and optionally forms part of a bicyclic ring system, or is optionally fused to one or two aryl or heteroaryl rings, or to one or two saturated or partially unsatd. cycloalkyl or heterocyclic rings, each of which rings and ring systems is optionally substituted. Y1 = -N(R1)(R2), -CH2-C(O)-N(R1)(R2), halogen, and H (R1 and R2 = H, L1, Cy1, and -L1-Cy1). Y2 = chemical bond or N(R0) (R0 = H, alkyl, aryl, aralkyl, and acyl); Ak1 = C1-C6 alkylene, C1-C6-heteroalkylene (preferably, in which one -CH2- is replaced with -NH-, and more preferably -NH-CH2), C2-C6 alkenylene or C2-C6 alkynylene; Ar1 = arylene or heteroarylene, either of which is optionally substituted; and Z1 = C(O)NH-Ay1 and CH:CHC(O)NH-Ay1 (Ay1 = aryl or heteroaryl, each of which is optionally substituted). For II: Cy2 = cycloalkyl, aryl, heteroaryl, or heterocyclyl; X1 = covalent bond, M1-L2-M1, and L2-M2-L2 (L2 = chemical bond, C1-C4 alkylene, C2-C4 alkenylene, and C2-C4 alkynylene, provided that L2 is not a chemical bond when X1 is M1-L2-M1; M1 = -O-, -N(R7)-, -S-, -S(O)-, S(O)2-, -S(O)2N(R7)-, -N(R7)S(O)2-, -C(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)-O- and -OC(O)NH- (R7 = H, alkyl, aryl, aralkyl, acyl, heterocyclyl, and heteroaryl); and M2 = M1, heteroarylene, and heterocyclylene, either of which rings is optionally substituted). Ar2 = arylene or heteroarylene, each of which is optionally substituted; R5 and R6 = H, alkyl, aryl, and aralkyl; q is 0 or 1; and Ay2 is a 5-6 membered cycloalkyl, heterocyclyl, or heteroaryl substituted with an amino or hydroxy moiety (preferably these groups are ortho to the amide N to which Ay2 is attached) and further optionally substituted; provided that when Cy2 is naphthyl, X1 is -CH2-, Ar2 is Ph, R5 and R6 are H, and q is 0 or 1, Ay2 is not Ph or o-hydroxyphenyl. Although the methods of preparation are not claimed, hundreds of example preps. are included.

IT 503040-12-8P, N-(2-Aminophenyl)-4-[(9-chloro-3-methyl-4-oxo-4H-isoxazolo[4,3-c]quinolin-5-yl)methyl]benzamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503040-12-8 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)methyl]- (9CI) (CA INDEX NAME)



IT 503040-11-7P, 4-[(9-Chloro-3-methyl-4-oxo-4H-isoxazolo[4,3-c]quinolin-5-yl)methyl]benzoic acid  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)


RN 503040-11-7 CAPLUS

CN Benzoic acid, 4-[(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)methyl]- (9CI) (CA INDEX NAME)




=&gt; d 4 bib abs hitstr

L4 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:175763 CAPLUS  
 DN 137:304252  
 TI Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1)  
 AU Norman, Bryan H.; Gruber, Joseph M.; Hollinshead, Sean P.; Wilson, Joseph W.; Starling, James J.; Law, Kevin L.; Self, Tracy D.; Tabas, Linda B.; Williams, Daniel C.; Paul, Donald C.; Wagner, Margaret M.; Dantzig, Anne H.  
 CS Eli Lilly and Company, Lilly Corporate Center, Discovery Chemistry Research, Indianapolis, IN, 46285, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(6), 883-886  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB Tricyclic isoxazoles were identified from a screen as a novel class of selective multidrug resistance protein (MRP1) inhibitors. From a screen lead, SAR efforts resulted in the preparation of LY 402913, which inhibits MRP1 and reverses drug resistance to MRP1 substrates, such as doxorubicin, in HeLa-T5 cells (EC50=0.90  $\mu$ M), while showing no inherent cytotoxicity. Addnl., LY 402913 inhibits ATP-dependent, MRP1-mediated LTC4 uptake into membrane vesicles prepared from the MRP1-overexpressing HeLa-T5 cells (EC50=1.8  $\mu$ M). LY 402913 also shows selectivity (.apprx.22-fold) against the related transporter, P-glycoprotein, in HL60/Adr and HL60/Vinc cells. Finally, when dosed in combination with the oncolytic MRP1 substrate vincristine, LY 402913 delays the growth of MRP1-overexpressing tumors in vivo.  
 IT 246238-46-0P 246238-55-1P 246238-56-2P  
 246238-59-5P 246238-60-8P 246238-62-0P  
 246238-64-2P 246238-66-4P 246238-68-6P  
 246239-19-0P 246239-34-9P 246239-38-3P  
 246239-66-7P 246239-68-9P 472996-58-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (tricyclic isoxazoles are novel inhibitors of multidrug resistance protein (MRP1))  
 RN 246238-46-0 CAPLUS  
 CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 246238-55-1 CAPLUS  
 CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



10676089


RN 246238-56-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 246238-59-5 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-60-8 CAPLUS

CN Benzeneacetamide, N-1,3-benzodioxol-5-yl-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)



RN 246238-62-0 CAPLUS


CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 246238-64-2 CAPLUS


CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10676089




RN 246238-66-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-68-6 CAPLUS

CN Benzoic acid, 4-[[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 246239-19-0 CAPLUS


CN Benzeneacetamide, N-[4-(aminosulfonyl)phenyl]-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)



RN 246239-34-9 CAPLUS


CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

10676089




RN 246239-38-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-hydroxy-3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-66-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 246239-68-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 472996-58-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



10676089




IT 246238-22-2 246239-75-8 472996-37-5  
472996-40-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(tricyclic isoxazoles are novel inhibitors of multidrug resistance  
protein (MRP1))


RN 246238-22-2 CAPLUS

CN Benzamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-  
yl)phenyl]methyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 246239-75-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-  
yl)-N-methyl-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 472996-37-5 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[2-(3,4,5-  
trimethoxyphenoxy)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 472996-40-0 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[[[(3,4,5-

10676089

trimethoxyphenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




IT 246238-13-1P 246238-45-9P 246240-20-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(tricyclic isoxazoles are novel inhibitors of multidrug resistance protein (MRP1))


RN 246238-13-1 CAPLUS

CN 3-Isioxazolecarboxamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 246238-45-9 CAPLUS

CN Benzeneacetic acid, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)



RN 246240-20-0 CAPLUS

CN Benzeneacetyl chloride, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)



IT 246153-40-2P 246238-14-2P 246238-15-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(tricyclic isoxazoles are novel inhibitors of multidrug resistance)


10676089

protein (MRP1))

RN 246153-40-2 CAPLUS


CN 3-Isoxazolecarboxamide, N-[(1R,2R)-6-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-methyl-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 246238-14-2 CAPLUS

CN 3-Isobutyl-5-methyl-2,3-dihydro-2H-indeno[1,2-b]isoxazolo[4,3-c]quinolin-6-ylidene-1H-imidazole-4-carboxamide, (1R,2R)-, (9CI) (CA INDEX NAME)



RN 246238-15-3 CAPLUS

CN 3-Isobutyl-5-methyl-2,3-dihydro-2H-indeno[1,2-b]isoxazolo[4,3-c]quinolin-6-ylidene-1H-imidazole-4-carboxamide, (1R,2R)-, (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10676089

=> d his

(FILE 'HOME' ENTERED AT 14:17:08 ON 14 JAN 2003)

FILE 'MEDLINE' ENTERED AT 14:17:17 ON 14 JAN 2003

L1	482 S MRP1
L2	211 S L1 AND INHIBIT?
L3	63 S L2 AND COMPOUND?
L4	3 S L3 AND REVIEW?
L5	60 S L3 NOT L4
L6	8 S L5 AND STRUCTURE?

=>

=>